A new clinical trial has been launched using patients' own immune systems to fight prostate cancer cells. Patients with advanced hormone refractory prostate cancer who have failed to respond to chemotherapy may qualify for this unique clinical trial.
Canton, Ohio (PRWEB) October 2, 2009 -- A new clinical trial has been launched using patients' own immune systems to fight prostate cancer cells. Patients with advanced hormone refractory prostate cancer who have failed to respond to chemotherapy currently have no viable options available. There is an experimental agent which is a monoclonal antibody that attacks the T-lymphocytes. Those lymphocytes' function is to weaken the immune system. By reducing the number of T-lymphocytes, the patient's immune system is augmented and strenthened producing antibodies that would potentially attack cancer cells.
A nationwide, placebo-controlled, clinical trial was recently launched where patients with prostate cancer who have received chemotherapy before will be treated with this monoclonal antibody. Preliminary previous trials using this compound in patients with melanoma and other cancers have produced encouraging results that made investigators conduct this large, clinical trial for prostate cancer patients.
Researchers involved in this innovative and relatively safe treatment (including Gabrail Cancer Center, Canton, Ohio) are trying to find out if this agent will produce an additional weapon to fight prostate cancer especially since there are no alternative therapies available. Log on to www.GabrailCancerCenter.com or call (330) 492-3345, for more information.
# # #
Read the full story at http://www.prweb.com/releases/2009/10/prweb2971344.htm.
Copyright©2009 Vocus, Inc.
All rights reserved